Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dac g 12 is a profilin protein derived from Dactylis glomerata, commonly known as cocksfoot or orchard grass. As a member of the profilin family, it functions as an actin-binding protein involved in the regulation of the cytoskeleton and signal transduction within the plant cell. In the context of human health, Dac g 12 is recognized as a minor allergen but acts as a significant pan-allergen due to its high structural conservation across various plant species, including grasses, weeds, and trees. This conservation often leads to cross-reactivity, contributing to pollen-food allergy syndrome where sensitized individuals react to various fruits and vegetables. In clinical practice, Dac g 12 is a target for diagnostic testing and allergen-specific immunotherapy (AIT). While not a traditional drug target like an enzyme or receptor, it is the molecular entity against which immune tolerance is sought in patients suffering from grass pollen-induced allergic rhinitis and asthma. Therapeutic approaches involve the controlled exposure to the allergen to modulate the immune system, specifically by increasing regulatory T cells and inducing the production of blocking IgG4 antibodies. Understanding the sensitization profile to Dac g 12 helps clinicians predict potential cross-reactivities and tailor immunotherapy components for better patient outcomes.
Allergen-specific immunotherapy (AIT) works by inducing immune tolerance through the administration of increasing doses of the allergen, shifting the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated regulatory profile, thereby reducing IgE-mediated mast cell degranulation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dactylis glomerata allergen 12 (Dac g 12).